Description: This article discusses the potential characteristics of health care reform and the associated impact on small insurance companies.

Description: Authors demonstrate the use of the claim reserve run-out test for the long-term A&H products. They present the method of this test and show a numerical illustration to depict interpretations of testing results.

Description: Source: This document is a whitepaper sourced from a health insurance industry analysis. It provides a detailed overview of the evolution and strategic importance of voluntary benefits within employer-sponsored health plans in the United States. Intent: The paper aims to inform healthcare stakeholders—particularly employers, insurers, and HR professionals—about the role of voluntary benefits in filling coverage gaps left by major medical plans. It outlines the historical development, market drivers, regulatory context (especially post-ACA), and future trends, with a focus on personalization, digital integration, and financial protection. Value: This resource offers practical insights and strategic guidance for enhancing benefits design and employee engagement.

Description: Discussion of recent developments in the taxation of noncoordinated benefits such as fixed indemnity, hospital indemnity, and specified disease insurance policies. Developments include a recent Chief Counsel Advice Memorandum and proposed triagency rulemaking that would impact non coordinated benefits.

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: There are many ways to actively utilize BE approaches – and implementing these important tools can help insurers in many ways.

Description: A humorous look at the spring 2013 activities that a health care actuary working on individual or small group health care reform would be involved in.

Description: New research shows that we often make sub-optimal choices, when selecting a health insurance plan, that lead to unnecessary out-of-pocket expenditu

Description: Joe Wurzburger, Staff Fellow at the SOA, shares his views and insights about the health care industry in general and the Health Section's role in particular.

Description: Discussion of recent laws and regulatory changes that have provided Medicare Advantage plans greater flexibility in benefit offerings and plan designs.